Incidence of Primary Cancers and Intracranial Tumour Recurrences in Growth Hormone-Treated and Untreated Adult Hypopituitary Patients: Analyses from HypoCCS.

Research output: Contribution to journalArticle

Abstract

Speculation remains that growth hormone (GH) treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenoma (PA) and craniopharyngioma (CP).

Details

Authors
  • Christopher J Child
  • Daniel Conroy
  • Alan G Zimmermann
  • Whitney Woodmansee
  • Eva Marie Erfurth
  • Leslie Robison
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Endocrinology and Diabetes
Original languageEnglish
Pages (from-to)779-790
JournalEuropean Journal of Endocrinology
Volume172
Issue number6
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes